Friday, June 13, 2008

GSK's Witty and his "3D Plan"

GlaxoSmithKline will "diversify and derisk" the company to help provide strong fuel share price growth combined with and give investors fewer "nasty surprises", according to Andrew Witty, the new chief executive of Britain's biggest drugs company.


The third "D", you ask?

Why, decruitment, of course.

No comments: